Welcome to our dedicated page for Cingulate news (Ticker: CING), a resource for investors and traders seeking the latest updates and insights on Cingulate stock.
Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical company pioneering Precision Timed Release™ (PTR™) technology to develop advanced treatments for ADHD and anxiety disorders. This page serves as the definitive source for verified company updates, offering investors and healthcare professionals timely access to essential developments.
Find comprehensive coverage of clinical trial milestones, regulatory submissions, and strategic partnerships shaping Cingulate's innovative pipeline. Our curated news collection includes updates on lead candidate CTx-1301's FDA review process, intellectual property expansions, and manufacturing advancements for PTR™-enabled therapies.
Key updates feature progress in addressing ADHD treatment limitations through single-dose efficacy solutions and developments in anxiety disorder management via novel drug delivery systems. All content undergoes rigorous verification to ensure alignment with financial reporting standards and medical accuracy.
Bookmark this page for streamlined access to Cingulate's latest biopharmaceutical innovations, patent filings, and market expansion initiatives. Stay informed about critical developments in precision drug delivery technology without promotional bias or speculative content.
Cingulate Inc. (NASDAQ: CING) announced that its Chairman and CEO, Shane J. Schaffer, will speak at a live Benzinga All Access event on April 18, 2023, at 10 a.m. CST. The discussion will focus on unmet needs in attention deficit/hyperactivity disorder (ADHD) and the expansion of Cingulate's Precision Timed Release™ (PTR™) platform into anxiety treatments. Schaffer will provide a company overview and recap recent clinical and business updates. The event will be available for viewing on Benzinga's YouTube channel and on Cingulate's website.
Cingulate is a biopharmaceutical company focused on developing next-generation pharmaceutical products aimed at improving treatment outcomes for patients with ADHD and potentially anxiety disorders through its PTR platform.
Cingulate Inc. (NASDAQ: CING) has completed the first cohort of its Phase 3 trial for CTx-1301, a treatment for adult ADHD, with results expected in 3Q 2023. This trial assesses the onset and duration of CTx-1301 in adults aged 18-55. Following this, Cingulate plans a pivotal Phase 3 fixed-dose trial for pediatric and adolescent patients slated to begin mid-2023. If successful, a New Drug Application (NDA) could be submitted in early 2024. CTx-1301 aims to provide entire active-day efficacy with once-daily dosing, enhancing the ADHD treatment landscape as no current stimulant medication offers this benefit.
Cingulate Inc. has announced a commercial agreement with Indegene to support the launch of its ADHD treatment, CTx-1301. This novel medication aims to provide a true, once-daily dose with efficacy lasting up to 16 hours, targeting a significant unmet need in the $20 billion ADHD market. The agreement includes comprehensive commercialization strategies designed to drive revenue and support Cingulate during its Phase 3 clinical trials, with results anticipated in Q3 2023. This partnership is expected to enhance Cingulate's operational efficiency and mitigate resource risks, positioning the company for a successful FDA approval and market entry.
FAQ
What is the current stock price of Cingulate (CING)?
What is the market cap of Cingulate (CING)?
